WO2002055542A3 - Hpv-spezifische peptide, die die bindung von hpv an die wirtszelle blockieren - Google Patents

Hpv-spezifische peptide, die die bindung von hpv an die wirtszelle blockieren Download PDF

Info

Publication number
WO2002055542A3
WO2002055542A3 PCT/DE2001/004399 DE0104399W WO02055542A3 WO 2002055542 A3 WO2002055542 A3 WO 2002055542A3 DE 0104399 W DE0104399 W DE 0104399W WO 02055542 A3 WO02055542 A3 WO 02055542A3
Authority
WO
WIPO (PCT)
Prior art keywords
hpv
binding
block
specific peptides
host cell
Prior art date
Application number
PCT/DE2001/004399
Other languages
English (en)
French (fr)
Other versions
WO2002055542A2 (de
Inventor
Esther Glastetter
Lutz Gissmann
Martin Mueller
Original Assignee
Deutsches Krebsforsch
Esther Glastetter
Lutz Gissmann
Martin Mueller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch, Esther Glastetter, Lutz Gissmann, Martin Mueller filed Critical Deutsches Krebsforsch
Publication of WO2002055542A2 publication Critical patent/WO2002055542A2/de
Publication of WO2002055542A3 publication Critical patent/WO2002055542A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Beschrieben werden HPV-spezifische Peptide, insbesondere HPV11 L1-spezifische Peptide, die an ein HPV-Kapsidprotein spezifisch binden und dadurch die Bindung des Virus an die Wirtzelle blockieren können. Die erfindungsgemässen Peptide eignen sich zur Prävention und/oder Behandlung einer HPV-Infektion (Papillomatose) oder einer damit in Zusammenhaug stehenden Erkrankung bzw. zur Verwendung als Leitstruktur zur Entwicklung entsprechender Arzneimittel.
PCT/DE2001/004399 2001-01-16 2001-11-21 Hpv-spezifische peptide, die die bindung von hpv an die wirtszelle blockieren WO2002055542A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10101890.8 2001-01-16
DE10101890A DE10101890A1 (de) 2001-01-16 2001-01-16 HPV-spezifische Peptide, die die Bindung von HPV an die Wirtszelle blockieren

Publications (2)

Publication Number Publication Date
WO2002055542A2 WO2002055542A2 (de) 2002-07-18
WO2002055542A3 true WO2002055542A3 (de) 2002-12-19

Family

ID=7670814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2001/004399 WO2002055542A2 (de) 2001-01-16 2001-11-21 Hpv-spezifische peptide, die die bindung von hpv an die wirtszelle blockieren

Country Status (2)

Country Link
DE (1) DE10101890A1 (de)
WO (1) WO2002055542A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7450754B2 (en) 2004-03-23 2008-11-11 Microsoft Corporation Radiometric calibration from a single image
CN105175538B (zh) * 2012-06-08 2019-01-08 厦门大学 抗hpv l1 蛋白的广谱单克隆抗体或其抗原结合片段及它们的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2794371A1 (fr) * 1999-10-07 2000-12-08 Biovector Therapeutics Fragments proteiquespolyepitopiques, leur obtention et leurs utilisations notamment en vaccination

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2794371A1 (fr) * 1999-10-07 2000-12-08 Biovector Therapeutics Fragments proteiquespolyepitopiques, leur obtention et leurs utilisations notamment en vaccination

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LUDMERER SW ET AL.: "A Neutralizing Epitope of Human Papillomavirus Type 11 Is Principally Described by a Continuous Set of Residues Which Overlap a Distinct Linear, Surface-Exposed Epitope", JOURNAL OF VIROLOGY, vol. 71, no. 5, May 1997 (1997-05-01), pages 3834 - 3839, XP002209569 *
RESSING ME ET AL.: "Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A*0201-Binding Peptides", THE JOURNAL OF IMMUNOLGY, vol. 154, 1995, pages 5934 - 5943, XP002209568 *
SCOTT JK & SMITH GP: "Searching for Peptide Ligands with an Epitope Library", SCIENCE, vol. 249, 27 July 1990 (1990-07-27), pages 386 - 390, XP000571645 *

Also Published As

Publication number Publication date
DE10101890A1 (de) 2002-08-01
WO2002055542A2 (de) 2002-07-18

Similar Documents

Publication Publication Date Title
WO2003077942A3 (en) Virus-like particles of human papillomavirus
EP1687329B8 (de) Optimierte expression von hpv-58-l1 in hefe
AU7545801A (en) Chimeric human papillomavirus (hpv) l1 molecules and uses therefor
EP1200109A4 (de) Verwendung von peptid-nukleinsäureverbindungen zur auslösung zellulärer immunantworten gegen hepatitis c
HK1085378A1 (en) Use of hpv16 and hpv18 as vaccine against one or more of oncogenic hpv type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
WO2002089731A3 (en) Agents for treatment of hcv and methods of use
DK1296711T3 (da) HPV-E7 til behandling af humant papillomavirus
AU2001270678A1 (en) Vaccine against foot-and-mouth disease
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
WO2000014244A3 (en) Treatment of cervical cancer
MY140664A (en) Optimized expression of hpv 45 l1 in yeast
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
HUS1500061I1 (hu) A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
WO2002004007A3 (en) Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
IL179138A0 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31,45, or 52
CA2424700A1 (en) Genetic immunisation against cervical carcinoma
WO2002055542A3 (de) Hpv-spezifische peptide, die die bindung von hpv an die wirtszelle blockieren
NZ516725A (en) Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus
WO1997004099A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
EP1427443A4 (de) Vakzine mit papilloma-virus-e-proteinen, die durch einen viralen vektor abgegeben werden
WO2004043996A3 (en) Ligands
JP2002532434A5 (de)
JP2006516386A5 (de)
AU2002317474A1 (en) Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP